一般演題１５

[O15-2] 生物学的製剤治療歴別のクローン病患者に対するグセルクマブとウステキヌマブの有効性: GALAXI試験

*松岡 克善¹、Silvio Danese²、Anita Afzali³、Remo Panaccine⁴、Julián Panés⁵、Walter Reinisch⁶、Natalie A. Terry⁷、Leonardo Salese⁷、Rian Van Rampelbergh⁷、Kitty Yuen Yi Wan⁷、Zijiang Yang⁷、Jewel Johanns⁷、吉越 真一⁸、佐々木 絢子⁸、Marcin Zmudziński⁹、Eran Zittan¹⁰、Vipul Jairath¹¹、David T. Rubin¹² (1. 東邦大学医療センター佐倉病院消化器内科、2. IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University、3. University of Cincinnati College of Medicine、4. University of Calgary、5. Hospital Clínic de Barcelona, IDIBAPS、6. Medical University of Vienna、7. Janssen Research & Development、8. ヤンセンファーマ株式会社、9. Gastromed, Gastrology and Endoscopy Center、10. The Abraham and Sonia Rochlin IBD Unit, Department of Gastroenterology and Liver Diseases, Emek Medical Center、11. Schulich School of Medicine & Dentistry, Western University、12. University of Chicago Medicine Inflammatory Bowel Disease Center )